These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

473 related articles for article (PubMed ID: 27712122)

  • 21. Visfatin/PBEF/Nampt and resistin expressions in circulating blood monocytes are differentially related to obesity and type 2 diabetes in humans.
    Laudes M; Oberhauser F; Schulte DM; Freude S; Bilkovski R; Mauer J; Rappl G; Abken H; Hahn M; Schulz O; Krone W
    Horm Metab Res; 2010 Apr; 42(4):268-73. PubMed ID: 20091460
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Serum visfatin and its relation to insulin resistance and inflammation in type 2 diabetic patients with and without macroangiopathy.
    Alghasham AA; Barakat YA
    Saudi Med J; 2008 Feb; 29(2):185-92. PubMed ID: 18246224
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Obesity and Cardiovascular Risk: Variations in Visfatin Gene Can Modify the Obesity Associated Cardiovascular Risk. Results from the Segovia Population Based-Study. Spain.
    Martínez Larrad MT; Corbatón Anchuelo A; Fernández Pérez C; Pérez Barba M; Lazcano Redondo Y; Serrano Ríos M;
    PLoS One; 2016; 11(5):e0153976. PubMed ID: 27166797
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Leucocytes are a major source of circulating nicotinamide phosphoribosyltransferase (NAMPT)/pre-B cell colony (PBEF)/visfatin linking obesity and inflammation in humans.
    Friebe D; Neef M; Kratzsch J; Erbs S; Dittrich K; Garten A; Petzold-Quinque S; Blüher S; Reinehr T; Stumvoll M; Blüher M; Kiess W; Körner A
    Diabetologia; 2011 May; 54(5):1200-11. PubMed ID: 21298414
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of a hypocaloric diet on serum visfatin in obese non-diabetic patients.
    de Luis DA; Gonzalez Sagrado M; Conde R; Aller R; Izaola O; Romero E
    Nutrition; 2008 Jun; 24(6):517-21. PubMed ID: 18343636
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Serum visfatin levels in a group of Egyptian obese individuals.
    Reda R; Shehab A; Soliman D; Gabr A; Abbass A
    Egypt J Immunol; 2011; 18(1):25-32. PubMed ID: 23082477
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Plasma levels of PBEF/Nampt/visfatin are decreased in patients with liver cirrhosis.
    de Boer JF; Bahr MJ; Böker KH; Manns MP; Tietge UJ
    Am J Physiol Gastrointest Liver Physiol; 2009 Feb; 296(2):G196-201. PubMed ID: 19074645
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adipocytes as a source of increased circulating levels of nicotinamide phosphoribosyltransferase/visfatin in active acromegaly.
    Olarescu NC; Ueland T; Lekva T; Dahl TB; Halvorsen B; Aukrust P; Bollerslev J
    J Clin Endocrinol Metab; 2012 Apr; 97(4):1355-62. PubMed ID: 22319029
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of olmesartan vs irbesartan on metabolic parameters and visfatin in hypertensive obese women.
    De Luis DA; Conde R; Gonzalez Sagrado M; Aller R; Izaola O; Perez Castrillon JL; Romero E; Castro MJ
    Eur Rev Med Pharmacol Sci; 2010 Sep; 14(9):759-63. PubMed ID: 21061834
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The relationship between visfatin and serum concentrations of C-reactive protein, interleukin 6 in patients with metabolic syndrome.
    Hosseinzadeh-Attar MJ; Golpaie A; Foroughi M; Hosseinpanah F; Zahediasl S; Azizi F
    J Endocrinol Invest; 2016 Aug; 39(8):917-22. PubMed ID: 27023106
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The comparison of serum vaspin and visfatin concentrations in obese and normal weight women.
    Saboori S; Hosseinzadeh-Attar MJ; Yousefi Rad E; Hosseini M; Mirzaei K; Ahmadivand Z
    Diabetes Metab Syndr; 2015; 9(4):320-3. PubMed ID: 25470626
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Association of increased visfatin/PBEF/NAMPT circulating concentrations and gene expression levels in peripheral blood cells with lipid metabolism and fatty liver in human morbid obesity.
    Catalán V; Gómez-Ambrosi J; Rodríguez A; Ramírez B; Silva C; Rotellar F; Cienfuegos JA; Salvador J; Frühbeck G
    Nutr Metab Cardiovasc Dis; 2011 Apr; 21(4):245-53. PubMed ID: 20106640
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Full-length visfatin levels are associated with inflammation in women with polycystic ovary syndrome.
    Lajunen TK; Purhonen AK; Haapea M; Ruokonen A; Puukka K; Hartikainen AL; Savolainen MJ; Morin-Papunen L; Tapanainen JS; Franks S; Järvelin MR; Herzig KH
    Eur J Clin Invest; 2012 Mar; 42(3):321-8. PubMed ID: 21913913
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Selected adipokines and metabolic profiles in normal-weight women with abdominal obesity.
    Miazgowski T; Major-Gołuch A; Safranow K
    Pol Arch Med Wewn; 2012; 122(9):406-12. PubMed ID: 22814438
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Epicardial fat thickness: relationship with plasma visfatin and plasminogen activator inhibitor-1 levels in visceral obesity.
    Malavazos AE; Ermetici F; Cereda E; Coman C; Locati M; Morricone L; Corsi MM; Ambrosi B
    Nutr Metab Cardiovasc Dis; 2008 Oct; 18(8):523-30. PubMed ID: 18083357
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Circulating visfatin in obese non-diabetic patients in relation to cardiovascular risk factors, insulin resistance, and adipocytokines: a contradictory piece of the puzzle.
    de Luis DA; Sagrado MG; Aller R; Conde R; Izaola O
    Nutrition; 2010; 26(11-12):1130-3. PubMed ID: 19211226
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Visfatin in obese patients, relation with cardiovascular risk factors, a cross sectional study].
    de Luis DA; Ballesteros M; Ruiz E; Muñoz C; Penacho A; Iglesias P; Guzmán AL; Abreu C; Maldonado A; Delgado M; Martín LS; Puigdevall V; Romero E; Sagrado MG; Izaola O; Conde R;
    Med Clin (Barc); 2011 Jul; 137(5):199-203. PubMed ID: 21296365
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Visfatin may be a novel marker for identifying stages of essential hypertension in advanced age patients.
    Gunes F; Akbal E; Cakir E; Akyurek O; Altunbas M; Ozbek M
    Intern Med; 2012; 51(6):553-7. PubMed ID: 22449661
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Visfatin Serum Levels in Obese Type 2 Diabetic Patients: Relation to Proinflammatory Cytokines and Insulin Resistance.
    Hetta HF; Ez-Eldeen ME; Mohamed GA; Gaber MA; ElBadre HM; Ahmed EA; Abdellatief RB; Abd-ElBaky RM; Elkady A; Nafee AM; Zahran AM; Ahmad M
    Egypt J Immunol; 2018 Jun; 25(2):141-151. PubMed ID: 30600957
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Plasma visfatin level in women with polycystic ovary syndrome.
    Dıkmen E; Tarkun I; Cantürk Z; Cetınarslan B
    Gynecol Endocrinol; 2011 Jul; 27(7):475-9. PubMed ID: 20586547
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.